The most frequently reported treatment-related AEs (≥15%) were aspartate transaminase elevation (n=15, 40.5%), alanine transaminase elevation (n=15, 40.5%), hypertension (n=13, 35.1%), fatigue (n=12, 32.4%), decreased appetite (n=11, 29.7%), diarrhea (n=10, 27.0%), increased total bilirubin (n=8, 21.6%), increased direct bilirubin (n=8, 21.6%), rash or desquamation (n=8, 21.6%), proteinuria (n=7, 18.9%), fever (n=6, 16.2%), leukocytopenia (n=6, 16.2%), and neutropenia (n=6, 16.2%). Here, GPT is linked to neutropenia.